Aldeyra Therapeutics, Inc. (ALDX)
Develops eye drop and oral drugs to reduce harmful inflammation in immune diseases.
$1.58-0.00%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago-67.2%
The outlook
ALDX is trading near its 52-week low, well below its key moving averages, suggesting downward momentum. Analysts are strongly bullish with an average price target implying significant upside from current levels. The overall sentiment remains neutral despite the bullish consensus, reflecting the stock's weak recent technical position.
What’s behind the score
Analyst consensusStrong Buy — 1.5 avg of 5 analysts
Price trendBelow its 50- & 200-day averages
52-week range10% of the way from its 52-week low to high
Price targetAvg target +318% vs current price
Analyst price target
~12-month · 5 analysts$6.60average target+317.7% vs now
Now $1.58
Low $2.00High $13.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$95.3M
52-wk high
$6.18
52-wk low
$1.07
50-day avg
$1.82
200-day avg
$3.55
Trailing P/E
—